RDP is one part of Europe’s intellectual property ecosystem. Its purpose is to attract, stimulate and support investment and innovation in medicines development in Europe. The Commission’s proposal is to cut RDP by 2 years at a time when the European Council Conclusions asked to strengthen, rather than cut, the region’s incentives. If this happens, we will see not only a reduction in European competitiveness, but a significant reduction in patients’ access to medicines.